事件：公司发布2025年半年报，上半年实现营收11.7亿元，较去年同期增长约3.7亿元，同比+46%，主要是因为商业化药品的销售收入与上年同期相比增长，实现归母净亏损4.1亿元，同比亏损收窄，主要是因为公司提质增效卓有成效。特瑞普利单抗收入持续增长。拓益2025H1实现国内市场销售收入9.54亿元，同比增长约42%，拓益在中国内地已获批12项适应症，其中今年3、4月依次获批肝细胞癌(一线治疗)、...
Source Link事件：公司发布2025年半年报，上半年实现营收11.7亿元，较去年同期增长约3.7亿元，同比+46%，主要是因为商业化药品的销售收入与上年同期相比增长，实现归母净亏损4.1亿元，同比亏损收窄，主要是因为公司提质增效卓有成效。特瑞普利单抗收入持续增长。拓益2025H1实现国内市场销售收入9.54亿元，同比增长约42%，拓益在中国内地已获批12项适应症，其中今年3、4月依次获批肝细胞癌(一线治疗)、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.